SCHAUMBURG, Ill., August 9, 2012 — Fresenius Kabi today announced that is has launched Oxaliplatin Injection, USP.
Oxaliplatin Injection, USP, is a platinum-based drug used in combination with infusional 5-fluorouracil/leucovorin, and indicated for adjuvant therapy of stage III colon cancer in patients who have undergone complete resection of the primary tumor as well as for the treatment of advanced colorectal cancer.
"We are fully committed to our customers and the patients who rely on Oxaliplatin Injection as a therapy, and we are dedicated to the long-term manufacturing, sales and distribution of this product," said John Ducker, president and chief executive officer of Fresenius Kabi USA. "Today's launch further signifies the expansion of the APP oncology portfolio and our ongoing emphasis to meet customer and patient needs."
According to IMS, in 2011 the total U.S. market for Oxaliplatin Injection was $1.5 billion.
APP will offer the product in single and ten pack configurations including 100mg/20ml and 50mg/10ml strength options.
About Fresenius Kabi
Fresenius Kabi is focused on the care of critically and chronically ill patients inside and outside the hospital. Its portfolio of products comprises a wide range of IV drugs, infusion therapies, clinical nutrition products as well as the related medical devices and blood transfusion technologies. With a corporate philosophy of “caring for life,” the company’s goal is to improve the patient’s quality of life. Fresenius Kabi AG is a 100 percent subsidiary of the health care group Fresenius SE & Co. KGaA. For more information, visit www.fresenius-kabi.com.
The statements contained in this news release that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this news release include statements regarding our expectations, beliefs, hopes, goals, intentions, initiatives or strategies, including statements regarding the demand, supply and distribution of our products. Because these forward-looking statements involve risks and uncertainties, there are important factors that could cause actual results to differ materially from those in the forward-looking statements. These factors include, but are not limited to, the availability and pricing of ingredients used in the manufacture of pharmaceutical products and the ability to successfully manufacture products in a time-sensitive and cost effective manner. Additional relevant information concerning risks can be found in the Fresenius Kabi Pharmaceuticals Holding, Inc. 10-K for the fiscal year ending December 31, 2010 and other documents the company has filed with the Securities and Exchange Commission. The information contained in this news release is as of the date of this release. Fresenius Kabi Pharmaceuticals Holding, Inc. does not assume any obligation to update or revise these forward-looking statements to conform the statement to actual results, new information, developments or changes in the Company’s expectations.
Senior Director, Communications & Government Affairs
Fresenius Kabi USA